Pay vs Performance Disclosure - USD ($)
|
12 Months Ended |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
| Pay vs Performance Disclosure |
|
|
|
|
| Pay vs Performance Disclosure, Table |
PAY VERSUS PERFORMANCE In accordance with Item 402(v) of Regulation S-K, the Company is required to disclose pay versus performance by comparing compensation amounts previously reported for the last four calendar years to the SEC’s definition of “Compensation Actually Paid” for such years. Also as required by the SEC, this section compares Compensation Actually Paid to various measures used to gauge performance at SIGA. Compensation Actually Paid is a required disclosure item, the amount of which is calculated in accordance with SEC rules. Such measure was not incorporated into the philosophy and strategy of compensation-setting set forth in the “Compensation Discussion and Analysis” of this proxy statement. Pay Versus Performance Table | Year | | | Summary
Compensation
Table Total for
PEO1 | | | Compensation
Actually Paid to
PEO2 | | | Average
Summary
Compensation
Table Total for
Non-PEO Named
Executive
Officers3 | | | Average
Compensation
Actually Paid to
Non-PEOs
Named Executive
Officers4, | | | Value of initial fixed $100
investment based on: | | | Net Income | | | Operating Income
(Pre-Tax)6 | | | Total
Shareholder
Return | | | Peer Group
Total
Shareholder
Return5 | | 2023 | | | $1,825,856 | | | $1,825,856 | | | $1,399,930 | | | $1,373,478 | | | $157 | | | $115 | | | $68,068,826 | | | $83,621,165 | 2022 | | | $1,738,912 | | | $1,738,912 | | | $993,871 | | | $993,871 | | | $176 | | | $111 | | | $33,904,806 | | | $42,700,166 | 2021 | | | $1,688,264 | | | $1,688,264 | | | $1,285,045 | | | $1,269,045 | | | $158 | | | $125 | | | $69,450,766 | | | $89,092,799 | 2020 | | | $1,639,090 | | | $1,639,090 | | | $1,280,950 | | | $1,354,729 | | | $152 | | | $126 | | | $56,342,010 | | | $84,500,630 |
(1)
| Amount included here is the amount in the “Total” column from the Summary Compensation Table (“SCT”) for the principal executive officer (“PEO”) for the applicable year. For each covered year (i.e. 2020-2023), our PEO was Dr. Gomez. |
(2)
| “Compensation Actually Paid” is calculated by starting with the amounts reported for the PEO in the “Total” column of the SCT for the applicable year, with such amounts adjusted for stock based compensation. The PEO received no stock based compensation during the years presented. |
(3)
| Amount included here is the average of the amounts in the “Total” column from the SCT for the applicable year for each of the other non-PEO NEOs. For 2023, our non-PEO NEOs were: Messrs. Luckshire, Hruby and Varma. For 2022, 2021 and 2020, our non-PEO NEOs were Messrs. Luckshire and Hruby and Ms. Robin E. Abrams (former General Counsel and Chief Administrative Officer). The 2022 amount was impacted by the resignation of Ms. Abrams, effective April 18, 2022. The 2023 amount includes compensation paid to Dr. Varma, pro-rated based on his commencement date with the Company. |
(4)
| In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Average Total Compensation for the NEOs as a group for each year to determine the compensations “actually paid”. |
Year | | | Reported Summary
Compensation Table for
Non-PEO NEOs | | | Average Reported
Value of
Equity Awards | | | Total Average
Equity Award
Adjustments(a) | | | Average Compensation
“Actually Paid” to
Non-PEO NEOs | 2023 | | | $1,399,930 | | | $(283,333) | | | $256,881 | | | $1,373,478 | 2022 | | | $993,871 | | | — | | | — | | | $993,871 | 2021 | | | $1,285,045 | | | — | | | $(16,000) | | | $1,269,045 | 2020 | | | $1,280,950 | | | — | | | $73,779 | | | $1,354,729 |
a)
| The amounts added or deducted in calculating the total average equity award adjustments are as follows: |
Year | | | Year-End Fair
Value of Equity
Awards Granted
During Applicable
Year | | | Change in
Fair Value as of Year-
End of Any Prior
Year Awards that
Remain Unvested
as of Year-End | | | Change in Fair
Value as of the
Vesting Date of Any
Prior Year Awards
that Vested During
Applicable Year | | | Total Equity Value
Reflected in
Compensation
Actually Paid | 2023 | | | $256,881 | | | — | | | — | | | $256,881 | 2022 | | | — | | | — | | | — | | | — | 2021 | | | — | | | — | | | $(16,000) | | | $(16,000) | 2020 | | | — | | | $44,445 | | | $29,334 | | | $73,779 |
(5)
| The peer group, for purposes of this analysis, is the Nasdaq Biotechnology Index. The company’s stock performance relative to the Nasdaq Biotechnology Index is disclosed in the Company’s Form 10-K. |
(6)
| Operating income (pre-tax) is a financial measure that is consistent with U.S. GAAP that is considered by the Company as part of its executive compensation program. The Compensation Committee reviews a variety of performance goals and metrics for the purpose of awarding compensation to executive officers that are consistent with the Company’s overall compensation philosophy and the long-term interests of its shareholders. Among these, the Compensation Committee has identified operating income (pre-tax) as the most important financial performance measure (that is not otherwise required to be disclosed in the table above) used by the Company to link compensation actually paid to its NEOs for the year ended December 31, 2023 to the Company’s performance. |
|
|
|
|
| Company Selected Measure Name |
Operating income (pre-tax)
|
|
|
|
| Named Executive Officers, Footnote |
(1)
| Amount included here is the amount in the “Total” column from the Summary Compensation Table (“SCT”) for the principal executive officer (“PEO”) for the applicable year. For each covered year (i.e. 2020-2023), our PEO was Dr. Gomez. |
(3)
| Amount included here is the average of the amounts in the “Total” column from the SCT for the applicable year for each of the other non-PEO NEOs. For 2023, our non-PEO NEOs were: Messrs. Luckshire, Hruby and Varma. For 2022, 2021 and 2020, our non-PEO NEOs were Messrs. Luckshire and Hruby and Ms. Robin E. Abrams (former General Counsel and Chief Administrative Officer). The 2022 amount was impacted by the resignation of Ms. Abrams, effective April 18, 2022. The 2023 amount includes compensation paid to Dr. Varma, pro-rated based on his commencement date with the Company. |
|
|
|
|
| Peer Group Issuers, Footnote |
(5)
| The peer group, for purposes of this analysis, is the Nasdaq Biotechnology Index. The company’s stock performance relative to the Nasdaq Biotechnology Index is disclosed in the Company’s Form 10-K. |
|
|
|
|
| PEO Total Compensation Amount |
$ 1,825,856
|
$ 1,738,912
|
$ 1,688,264
|
$ 1,639,090
|
| PEO Actually Paid Compensation Amount |
1,825,856
|
1,738,912
|
1,688,264
|
1,639,090
|
| Non-PEO NEO Average Total Compensation Amount |
1,399,930
|
993,871
|
1,285,045
|
1,280,950
|
| Non-PEO NEO Average Compensation Actually Paid Amount |
$ 1,373,478
|
993,871
|
1,269,045
|
1,354,729
|
| Adjustment to Non-PEO NEO Compensation Footnote |
(4)
| In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Average Total Compensation for the NEOs as a group for each year to determine the compensations “actually paid”. |
Year | | | Reported Summary
Compensation Table for
Non-PEO NEOs | | | Average Reported
Value of
Equity Awards | | | Total Average
Equity Award
Adjustments(a) | | | Average Compensation
“Actually Paid” to
Non-PEO NEOs | 2023 | | | $1,399,930 | | | $(283,333) | | | $256,881 | | | $1,373,478 | 2022 | | | $993,871 | | | — | | | — | | | $993,871 | 2021 | | | $1,285,045 | | | — | | | $(16,000) | | | $1,269,045 | 2020 | | | $1,280,950 | | | — | | | $73,779 | | | $1,354,729 |
a)
| The amounts added or deducted in calculating the total average equity award adjustments are as follows: |
Year | | | Year-End Fair
Value of Equity
Awards Granted
During Applicable
Year | | | Change in
Fair Value as of Year-
End of Any Prior
Year Awards that
Remain Unvested
as of Year-End | | | Change in Fair
Value as of the
Vesting Date of Any
Prior Year Awards
that Vested During
Applicable Year | | | Total Equity Value
Reflected in
Compensation
Actually Paid | 2023 | | | $256,881 | | | — | | | — | | | $256,881 | 2022 | | | — | | | — | | | — | | | — | 2021 | | | — | | | — | | | $(16,000) | | | $(16,000) | 2020 | | | — | | | $44,445 | | | $29,334 | | | $73,779 |
|
|
|
|
| Compensation Actually Paid vs. Total Shareholder Return |
The relationship between (1) compensation actually paid to the PEO and the average of compensation actually paid to NEOs other than the PEO and (2) cumulative total shareholder return on the common stock of the Company and cumulative total shareholder return on the stock of NASDAQ Biotech Composite Index for the last four completed fiscal years is shown in Figure 1. Figure 1: Compensation Actually Paid versus Total Shareholder Return (“TSR”) 
|
|
|
|
| Compensation Actually Paid vs. Net Income |
The relationship between (1) compensation actually paid to the PEO and the average of compensation actually paid to NEOs other than the PEO and (2) net income of the Company for the last four completed fiscal years is shown in Figure 2. Figure 2: Compensation Actually Paid versus Net Income 
|
|
|
|
| Compensation Actually Paid vs. Company Selected Measure |
The relationship between (1) compensation actually paid to the PEO and the average of compensation actually paid to NEOs other than the PEO and (2) operating income (pre-tax) of the Company for the last four completed fiscal years is shown in Figure 3. Figure 3: Compensation Actually Paid versus Operating Income (Pre-Tax) 
|
|
|
|
| Total Shareholder Return Vs Peer Group |
The relationship between (1) compensation actually paid to the PEO and the average of compensation actually paid to NEOs other than the PEO and (2) cumulative total shareholder return on the common stock of the Company and cumulative total shareholder return on the stock of NASDAQ Biotech Composite Index for the last four completed fiscal years is shown in Figure 1. Figure 1: Compensation Actually Paid versus Total Shareholder Return (“TSR”) 
|
|
|
|
| Tabular List, Table |
List of Performance Measures The Company utilizes other important financial measures to consider for compensation actually paid to its NEOs performance as set forth in the table below. Operating Income (Pre-Tax) | Total Product Sales and Supportive Services Revenues | Total Revenues | International Sales Revenue | Net Income | Diluted Earnings per Share | Relative TSR |
|
|
|
|
| Total Shareholder Return Amount |
$ 157
|
176
|
158
|
152
|
| Peer Group Total Shareholder Return Amount |
115
|
111
|
125
|
126
|
| Net Income (Loss) |
$ 68,068,826
|
$ 33,904,806
|
$ 69,450,766
|
$ 56,342,010
|
| Company Selected Measure Amount |
83,621,165
|
42,700,166
|
89,092,799
|
84,500,630
|
| PEO Name |
Dr. Gomez.
|
Dr. Gomez.
|
Dr. Gomez.
|
Dr. Gomez.
|
| Measure:: 1 |
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
| Name |
Operating Income (Pre-Tax)
|
|
|
|
| Measure:: 2 |
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
| Name |
Total Product Sales and Supportive Services Revenues
|
|
|
|
| Measure:: 3 |
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
| Name |
Total Revenues
|
|
|
|
| Measure:: 4 |
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
| Name |
International Sales Revenue
|
|
|
|
| Measure:: 5 |
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
| Name |
Net Income
|
|
|
|
| Measure:: 6 |
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
| Name |
Diluted Earnings per Share
|
|
|
|
| Measure:: 7 |
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
| Name |
Relative TSR
|
|
|
|
| Non-PEO NEO | Reported Value of Equity Awards [Member] |
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
| Adjustment to Compensation, Amount |
$ (283,333)
|
$ 0
|
$ 0
|
$ 0
|
| Non-PEO NEO | Equity Award Adjustments [Member] |
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
| Adjustment to Compensation, Amount |
256,881
|
0
|
(16,000)
|
73,779
|
| Non-PEO NEO | Year-End Fair Value of Equity Awards Granted During Applicable Year [Member] |
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
| Adjustment to Compensation, Amount |
256,881
|
0
|
0
|
0
|
| Non-PEO NEO | Change in Fair Value as of Year-End of Any Prior Year Awards that Remain Unvested as of Year-End [Member] |
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
| Adjustment to Compensation, Amount |
0
|
0
|
0
|
44,445
|
| Non-PEO NEO | Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year [Member] |
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
| Adjustment to Compensation, Amount |
$ 0
|
$ 0
|
$ (16,000)
|
$ 29,334
|